- Home
- AEMD vs HCWB Comparison
AEMD vs HCWB Comparison
Compare AEMD & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEMD | HCWB |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.7M |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AEMD | HCWB |
|---|---|---|
| Price | $2.13 | $0.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $15.00 | ★ $35.00 |
| AVG Volume (30 Days) | 62.4K | ★ 21.7M |
| Earning Date | 02-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,099,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.31 | $0.22 |
| 52 Week High | $5.89 | $17.80 |
Technical Indicators
Market Signals| Indicator | AEMD | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 33.99 |
| Support Level | $1.86 | N/A |
| Resistance Level | $2.79 | $0.78 |
| Average True Range (ATR) | 0.20 | 0.15 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 70.43 | 1.39 |
Price Performance
Historical ComparisonAbout AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.